Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan ; day:26 ; month:10 ; year:2023 ; pages:1-10
Drugs - real world outcomes ; (26.10.2023), 1-10
- Urheber
-
Iwasaki, Kotaro
Wakabayashi, Hiroki
Saiki, Atsuhito
Ueshiba, Hajime
Murakami, Yu
Matsuzawa, Yasuo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40801-023-00396-w
- URN
-
urn:nbn:de:101:1-2024011511454132938372
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Iwasaki, Kotaro
- Wakabayashi, Hiroki
- Saiki, Atsuhito
- Ueshiba, Hajime
- Murakami, Yu
- Matsuzawa, Yasuo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
Antifibrotic therapies to control cardiac fibrosis
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
Antifibrotic therapies to control cardiac fibrosis
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment
Antifibrotic therapies to control cardiac fibrosis
Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis